Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARC: Peg-IFN + Ribavirin in HBeAg-negative Chronic HBV
NCT00114361Phase 3Completed
- Sponsor
- Foundation for Liver Research
- Start
- Mar 2005
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Ribavirin + Peg IFN with Peg IFN + Placebo (2 arms). Primary endpoint: Combined presence of HBV DNA level < 10E4 copies/ml and ALT normalization. Started Mar 2005; status: completed.
02
Drugs
ribavirin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00114361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114361.